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 Objective: Rare disease
 Background: Fabry disease is an X-linked disorder. Due to deficiency of the enzyme a-galactosidase A, neutral glycosphin-
golipids (primarily globotriaosylceramide) progressively accumulate within lysosomes of cells in various organ 
systems, resulting in a multi-system disorder, affecting both men and women. Misdiagnosis and delayed diag-
nosis are common because of the nature of Fabry disease.
 Case Report: We report a case of Fabry disease with a p.R301X (c.901 C>T) mutation in a 39-year-old man who was being 
treated for chronic sclerosing glomerulonephritis for 2 years. Family screening tests showed that the proband’s 
mother, sister, and daughter had the same mutation with different phenotypes. Levels of a-galactosidase A 
were low in the proband and his mother and sister. Cornea verticillata and heart involvement were present in 
multiple family members. Agalsidase alfa treatment was started in patients where indicated.
 Conclusions: Pedigree analysis is still a powerful, readily available tool to identify individuals at risk for genetic diseases and 
allows earlier detection and management of disease.
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Background
Fabry disease (FD) (OMIM 301500) (http://www.ncbi.nlm.nih.
gov/entrez/query.fcgi?db=OMIM) is an X-linked disorder. It is 
caused by deficiency of the enzyme a-galactosidase A (EC 
3.2.1.22) (http://www.chem.qmul.ac.uk/iubmb/enzyme/). The 
GLA gene produces enzyme a-galactosidase A and is present on 
the long arm of chromosome Xq22.1. Due to deficiency of the 
enzyme a-galactosidase A, neutral glycosphingolipids (primari-
ly globotriaosylceramide) progressively accumulate within lyso-
somes of cells in various organ systems. Globotriaosylceramide 
gradually accumulates in endothelial cells, vascular smooth 
muscle cells, pericytes, renal epithelial cells, myocardial cells, 
and neurons, which leads progressively to cellular dysfunction, 
necrosis, apoptosis, inflammation, and fibrosis [1].
Demonstration of deficient activity of a-galactosidase in plas-
ma or leukocytes and showing GLA mutation are the primary 
diagnostic tools in men [1,2]. Female patients may have en-
zyme activity within the normal range; therefore, they should 
have their status determined by genotyping (analysis of the 
GLA gene mutation) [3].
The first clinical manifestations of the disease appear in child-
hood, and renal, cardiac, and cerebrovascular complications 
usually arise in adulthood. The clinical features of FD are ac-
roparesthesia and pain crises, angiokeratomas, gastrointesti-
nal symptoms, and corneal dystrophy. In later stages of dis-
ease, proteinuria, renal failure, left ventricular hypertrophy, 
arrhythmias, and stroke develop [1].
Misdiagnosis of the FD is an important problem. Sometimes it 
takes years between beginning of the symptoms and correct 
diagnosis. The Fabry Outcome Survey study showed that the 
mean time was 14.5 years for men and 16.8 years for wom-
en [4]. In another study, the recognition of the underlying diagno-
sis was delayed by 14 years in men and 19 years in women [5]. 
Therefore, it is important to examine the index cases. There are 
cases in which the clinical indicators of FD overlap with those of 
some rheumatic disorders, such as familial Mediterranean fe-
ver [6,7]. Retrospective studies found a significant delay in diag-
nosis of Fabry disease in ~40% of men and ~70% of women [7].
Phenotypic variability in the same family, in terms of involved 
organs and severity, was previously defined for M51I muta-
tion [8]. It has been defined in 8 Italian patients aged 22–58 
years. Six patients were female. The proband was a 22-year-
old female patient who had been suffering from recurrent fe-
ver of unknown origin, burning pain located in the hands and 
feet, and gastrointestinal disturbances. It took 10 years after 
the appearance of the first clinical manifestations to diagnose 
FD. The other female patient had cardiac involvement with dys-
pnea and arrhythmias. A 28-year-old man with no enzymatic 
activity showed serious cerebrovascular involvement, although 
the other patient, a 58-year-old man, was completely asymp-
tomatic. One of the daughters of the 58-year-old man had no 
enzymatic activity. She showed cerebral involvement and was 
also diagnosed with multiple sclerosis based on the presence 
of lesions of the corpus callosum on MRI.
This study reports the clinical, biochemical, and molecular char-
acterization of 4 members of the same family. The proband 
was being treated for chronic sclerosing glomerulonephritis 
for 2 years. Four members of the family showed the exonic 
p.R301X (c.901 C>T) nonsense GLA gene mutation, which is 
a disease causing mutation associated with the atypical phe-
notype (Figure 1). The p.R301X (c.901 C>T) mutation has pre-
viously been reported in families with FD, but here we report 
the clinical history of a family that highlights a phenotypic vari-
ability in terms of involved organs and severity [9].
Case Report
The proband was a 39-year-old man who was treated for chronic 
sclerosing glomerulonephritis over 2 years. Recently, he began 
to complain of fatigue, hypohidrosis, and Raynaud’s phenom-
enon. His physical examination showed angiokeratoma, grade 
3/6 systolic murmur on apex, and cornea verticillata. Laboratory 
evaluation showed hemoglobin 13.9 g/dl, white blood cell count 
6.73×103/µL, platelet count 1.96×105/µL, erythrocyte sedimen-
tation rate 6 mm/h, blood urea nitrogen 51 mg/dL, creatinine 
3.21 mg/dL, 24-h urinary protein 3.3 g/day, and other parame-
ters were in the normal ranges. Echocardiography showed left 
ventricular hypertrophy, mitral regurgitation (grade 1–2/4), and 
tricuspid regurgitation (grade 1/4). Electrocardiography was in 
normal range. At the time of intake his family history was un-
remarkable. We evaluated the patient with suspicion of FD. The 
patient had a pathogenic p.R301X (c.901 C>T) mutation and 
showed enzymatic activity of a-galactosidase 6.56 nmol/mg·h 
(normal range: 32–60 nmol/mg·h), which was below the nor-
mal value. Agalsidase alfa treatment was started.
Genetic and biochemical tests were extended to the proband’s 
family members. These analyses showed that the proband 
inherited the p.R301X (c.901 C>T) mutation from his moth-
er. She was a 63-year-old woman with enzymatic activity of 
5.8 nmol/mg·h (normal range: 32–60 nmol/mg·h) and with 
symptoms not clearly related to FD. She was taking 50 mg/day 
L-thyroxine for hypothyroidism and 50 mg/day metoprolol for 
palpitations. Her past medical history showed that she had 
acroparesthesia and neuropathic pain in her thirties. She be-
gan to have cardiac symptoms in the third decade. Physical 
examination showed blood pressure of 160/90 mmHg, grade 
2/6 systolic murmur on apex, angiokeratoma, and cornea ver-
ticillata. Echocardiography showed significant left ventricular 
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hypertrophy, electrocardiography showed normal sinus rhythm, 
and 24-h urinary protein was 31 mg/day. There was no neu-
rological or renal involvement.
The proband’s sister’s enzymatic activity was 12.8 nmol/mg·h 
(normal range: 32–60 nmol/mg·h). She began to complain of 
hyperhidrosis, palpitations, and neuropathic pain in her third 
decade of life. Physical examination showed blood pressure 
of 140/90 mmHg, grade 2/6 systolic murmur on aorta, angio-
keratoma, and cornea verticillata. Echocardiography showed 
significant left ventricular hypertrophy and mitral regurgita-
tion, and 24-h urinary protein was 712 mg/day.
Cerebral magnetic resonance imaging (MRI) was normal in all 
patients. Agalsidase alfa treatment were started in the moth-
er because of heart involvement, and in the sister for heart 
and kidney involvement in addition to low enzymatic activity.
The proband’s 6-year-old daughter’s genetic test showed that 
she had the same mutation and her enzymatic activity was in 
the normal range – 46.20 nmol/mg·h (32–60 nmol/mg·h). She 
does not have any symptoms associated with FD.
All patients gave written informed consent to participate in 
this study.
Peripheral blood samples were collected, using EDTA as an an-
ticoagulant, for detection of a-galactosidase A activity and ge-
netic analysis. a-Galactosidase A activity was measured by fluo-
rometric assay, as described by Blau et al. (2008) in an external 
laboratory (Duzen Laboratory, Ankara) [10]. Fabry disease was 
indicated when a-galactosidase A activity in blood was <32 
nmol/mg·h (normal range 32–60 nmol/mg·h). We also performed 
mutation analysis with an automated sequencing method that 
screened all 7 exons of GLA. The MiSeq next generation sequenc-
ing (NGS) platform (Illumina, San Diego, CA, USA) was used for 
GLA gene sequencing analysis. The manufacturer’s standard 
procedure was used while extracting genomic DNA using the 
QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany). IGV 2.3 
(Broad Institute) software was used for visualization of the data.
Figure 1.  Exonic p.R301X (c.901 C>T) nonsense GLA gene mutation.
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Relevant enzymatic and molecular data of the family are giv-
en in Table 1.
Discussion
The estimated incidence of FD in the general population is 1 
in 117 000 [11]. Newborn screening initiatives have found a 
high prevalence of the disease, as high as 1 in ~3100 new-
borns in Italy [12].
To date, >600 mutations have been described in the exons and 
introns of the GLA gene, and discrimination between patho-
logical and neutral mutations is difficult (http://fabry-data-
base.org/mutants/september 2015). Classically, clinical mani-
festations are more severe in male hemizygous subjects than 
in female heterozygotes. Recently, it was found that FD can 
also severely affect women, but progression of the disease to 
organ failure generally takes longer and the severity of symp-
toms are more variable than in men [4,5]. For this reason, ac-
curate follow-up is required for female patients, independent 
of enzymatic activity levels.
Misdiagnosis of the FD is common; it takes years (14–19 years) 
between beginning of the symptoms and correct diagnosis [4,5]. 
In our case, the patient was being treated for chronic scleros-
ing glomerulonephritis for 2 years, which is a relatively short 
time. Fabry disease may not be diagnosed until development 
of end-stage renal failure in patients with proteinuria. The fre-
quency of FD was 0.04% (2/5408) in men and 0% (0/3139) 
in women, and then 0.02% (2/8547) in all patients undergo-
ing dialysis in the Japan Fabry Disease Screening Study [13]. 
In Spain, 3650 samples from hemodialysis patients (18.5% of 
all patients undergoing hemodialysis in Spain) were tested 
and 11 new unrelated cases of Fabry disease (4 males and 7 
females, 0.003%) were diagnosed [14]. The prevalence of FD 
was detected as 0.17% in Turkish hemodialysis patients [15].
Although the average presentation age is 6–8 years in males, 
the proband’s symptoms began in his late thirties. His moth-
er’s and sister’s symptoms also began at about the same age. 
His 6-year-old daughter does not have symptoms. Suspicion, 
careful physical examination, and past medical history (includ-
ing acroparesthesia, heat and cold intolerance, and hypohidro-
sis) are very valuable.
In the M51I mutation, there were reports of cardiac, cerebral, 
and gastrointestinal involvement, but the kidneys are pro-
tected [8]. Another study evaluating intrafamilial phenotypic 
variability in 4 families (GLA gene mutations; p.R220X, p.C52Y, 
p.C172Y, p.R342X) with FD showed that renal and cardiac in-
volvements, angiokeratoma, and acroparesthesia are common 
findings [16]. Cerebral involvements are found only in p.C52Y 
and p.R342X mutations. In our patient’s p.R301X mutation, ce-
rebral and gastrointestinal involvement were absent.
European renal best practice recommends screening patients 
for Fabry disease when there is unexplained chronic kidney 
disease in men younger than 50 years and women of any age. 
In men, the activity of a-galactosidase A can be measured in 
plasma, blood cells, or dried blood spots. In women, mutation 
analysis is necessary, as enzyme measurement alone can miss 
over one-third of female Fabry patients [17]. Our proband pa-
tient was a 39-year-old man who was being treated for chronic 
sclerosing glomerulonephritis. His sister had renal involvement.
Cardiac symptoms, including left ventricular hypertrophy, ar-
rhythmia, angina, and dyspnea, are reported in 40–60% of pa-
tients with FD [1]. The prevalence of Fabry disease in primary 
cardiology practice with strictly defined otherwise unexplained 
LVH was 4% in males. Systematic screening is recommended 
in all men older than 30 years with LVH of unknown etiology 
for FD, even in the absence of obvious extracardiac manifesta-
tions [18]. Many characteristics of Fabry disease cardiomyop-
athy, with regard to electrocardiography and cardiac imaging, 
Kinship Proband Mother Sister Daughter
Age (year) 39 63 43 6
Mutation p.R301X p.R301X p.R301X p.R301X
Enzyme activity (nmol/mg·h) 6.56 5.8 12.8 46.2
Acroparesthesia + – + –
Angiokeratomas + – + –
Cornea verticillata + + + –
Kidney involvement + – + –
Heart involvement + + + –
Heat/cold intolerance + – + –
Table 1. Clinical presentation of patients.
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have been claimed. None of the criteria were specific enough 
(90%) to be used for definitive diagnosis of Fabry disease.
Cerebrovascular manifestations result from multifocal small-
vessel involvement and may include thromboses, seizures, 
paroxysmal hemiplegia, or hemianesthesia. Sensory neurons 
in spinal ganglia and small myelinated and unmyelinated fi-
bers are preferentially affected. As a result of these features 
and the frequent presence of lesions in MRI scans, FD is of-
ten misdiagnosed as multiple sclerosis [19]. Fabry disease may 
explain ~1% of all strokes in young people, including 3–5% of 
cryptogenic strokes. Early recognition of FD may help to initi-
ate appropriate treatment to decrease the risk of subsequent 
complications [20].
The European Fabry Working Group consensus recommends 
enzyme replacement therapy as soon as there are early clini-
cal signs of kidney, heart, or brain involvement for classically 
affected men. Classically affected women and men with non-
classical FD should be treated as soon as there are early clin-
ical signs of kidney, heart, or brain involvement, while treat-
ment may be considered in women with non-classical FD with 
early clinical signs that are considered to be due to FD [2].
Conclusions
In conclusion, our findings confirm the intrafamilial phenotyp-
ic variability in patients who have the same mutation. In the 
light of previous studies and results of the present report, it 
appears that heterozygous women could be affected as se-
verely as man and should not be considered as asymptomat-
ic carriers. Pedigree analysis remains a powerful, readily avail-
able tool to identify individuals at risk for genetic diseases.
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